CSA, cyclosporine; MAC, myeloablative conditioning; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; RIC, reduced-intensity conditioning.

Chang 2020¹⁹: PBSC included PBSC N = 76 (57.6%) as well as bone marrow transplant (BMT) + PBSC N = 50 (37.9%). Finke 2009²⁰: N = 21 (20%) had human leukocyte antigen (HLA)-C mismatch. Soiffer 2017²²: N = 9 (7%) unknown graft source. Walker 2016: included CNI (either CSA or TAC) combined with MTX or MMF. Luznik 2022³⁹: reported approach/IS therapy per randomly assigned therapy, whereas N = 15 in the CD34 selection arm of the trial received TAC/MTX or other as treatment noncompliance, and N = 9 in the PTCy arm received noncompliant therapy of TAC/MTX or other. Bleakley 2022³²: had all myeloablative regimens, but 72% high intensity and 28% intermediate intensity; the combined report summarized different trials, which varied in the delivered pharmacologic immune suppression (included TAC alone, TAC/MTX, or TAC/MMF) alongside the naïve T-cell depletion approach. Bolanos-Meade²⁵ 2023: age reported as mean (64.2 years, ±8.5 years). Luznik 2010²⁶: 1 related donor was an HLA-identical parent. Kanakry 2014³⁰: 1 patient had a 10/10 HLA matched familial donor (grouped here with the matched sibling donor group).